AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC
Shots:
- The P-III PACIFIC study involves assessing of Imfinzi vs PBO in patients with unresectable- Stage III- LA NSCLC whose disease had not progressed following concurrent platinum-based CRT.
- The updated post-hoc analyses demonstrated OS @4yrs. (49.6% vs 36.3%)- m-OS (47.5 vs 29.1mos); patients not progressed after 4yrs. (35% vs 19.5%) respectively- presented at ESMO
- The company also highlights the data of Imfinzi vs CT in the P-III CASPIAN study underscoring the long-term benefit in patients with ES-SCLC. The exploratory subgroup analysis demonstrated PFS ≥12mos. (17% vs 4.5%)- patients who were progression-free & had progression @1yr. (75% & 10%) chances of being alive @2yrs.respectively
Ref: AstraZeneca | Image: Al Jazeera
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com